CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors.
Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过继性细胞治疗(ACT)已被证明在治疗血液肿瘤方面高度有效,但传统的ACT方法在临床上治疗实体瘤效果不佳。与标准静脉给药方法相比,治疗性细胞的新型递送方法在实体瘤治疗中显示出前景,但少数已报道的方法利用了制造复杂且主要在肿瘤切除后或免疫豁免组织中证明适用性的生物材料。在此,我们设计了易于实施的注射用水凝胶,用于CAR-T 细胞和刺激性细胞因子的受控共递送,从而改善实体瘤的治疗。该材料独特的结构同时抑制了包封细胞因子的被动扩散,并允许包封细胞的主动运动,从而实现CAR-T 细胞的长期滞留、活力和激活。给药后产生的短暂炎症微环境提供了CAR-T 细胞的持续暴露,诱导肿瘤反应性CAR-T 表型,并提高治疗效果。
Adoptive cell therapy (ACT) has proven to be highly effective in treating blood cancers, but traditional approaches to ACT are poorly effective in treating solid tumors observed clinically. Novel delivery methods for therapeutic cells have shown promise for treatment of solid tumors when compared with standard intravenous administration methods, but the few reported approaches leverage biomaterials that are complex to manufacture and have primarily demonstrated applicability following tumor resection or in immune-privileged tissues.
Here, we engineer simple-to-implement injectable hydrogels for the controlled co-delivery of CAR-T cells and stimulatory cytokines that improve treatment of solid tumors. The unique architecture of this material simultaneously inhibits passive diffusion of entrapped cytokines and permits active motility of entrapped cells to enable long-term retention, viability, and activation of CAR-T cells.
The generation of a transient inflammatory niche following administration affords sustained exposure of CAR-T cells, induces a tumor-reactive CAR-T phenotype, and improves efficacy of treatment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。